Hepatocyte growth factor as a long-term predictor for total and cardiovascular mortality in patients on peritoneal dialysis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 9, 2013, Pages 453-459

  Janda, Katarzyna ^a   Krzanowski, Marcin ^a   Dumnicka, Paulina ^a   Kuśnierz Cabala, Beata ^a   Sorysz, Danuta ^a   Sułowicz, Władysław ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cardiovascular mortality; Hepatocyte growth factor; Peritoneal dialysis; Total mortality

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; INTERLEUKIN 18; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHORUS; SCATTER FACTOR; BIOLOGICAL MARKER;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY CALCIUM SCORE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OVERALL SURVIVAL; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; TREATMENT DURATION; AGED; ANALYSIS OF VARIANCE; ARTERIAL WALL THICKNESS; BLOOD; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMORBIDITY; ECHOGRAPHY; HYPERCHOLESTEROLEMIA; HYPEREMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MANOMETRY; METABOLISM; MIDDLE AGED; MORTALITY; OBESITY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; COMORBIDITY; ENDOTHELIUM, VASCULAR; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; HYPERCHOLESTEROLEMIA; HYPEREMIA; HYPERTENSION; INTERLEUKIN-18; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MANOMETRY; MIDDLE AGED; OBESITY; PERITONEAL DIALYSIS; SEVERITY OF ILLNESS INDEX; VASODILATION;

EID: 84887261752     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.1883     Document Type: Article

References (20)

1. Morishita R, Aoki M, Yo Y, Ogihara T. Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Endocr J. 2002; 49: 273-284.
2. Borawski J, Mysliwiec M. [Relevance of some growth factors to cardiovascular disease in maintenance haemodialysis patients]. Pol Merkur Lekarski. 2006; 21: 117-118. Polish.
3. Yang ZJ, Xu SL, Chen B, et al. Hepatocyte growth factor plays a critical role in the regulation of cytokine production and induction of endothelial progenitor cell mobilization: a pilot gene therapy study in patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2009; 36: 790-796.
4. Banquet S, Gomez E, Nicol L, et al. Arteriogenic therapy by intramyocardial sustained delivery of novel growth factor combination prevents chronic heart failure. Circulation. 2011; 124: 1059-1069.
5. Kwiatkowska E, Kedzierska K, Bober J, et al. Urinary hepatocyte growth factor indicates ischemia/reperfusion injury after kidney transplantation. Pol Arch Med Wewn. 2010; 120: 437-442.
6. Malatino LS, Mallamaci F, Benedetto FA, et al. Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end- stage renal disease. Am J Kidney Dis. 2000; 36: 945-952.
7. Watorek E, Paprocka M, Dus D, et al. Endostatin and vascular endothelial growth factor: potential regulators of endothelial progenitor cell number in chronic kidney disease. Pol Arch Med Wewn. 2011; 121: 296-302.
8. Komamura K, Miyazaki J, Imai E, et al. Hepatocyte growth factor gene therapy for hypertension. Methods Mol Biol. 2008; 423: 393-404.
9. Madonna R, Cevik C, Nasser M, De Caterina R. Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration. Thromb Haemost. 2012; 107: 656-661.
10. Zhu Y, Hojo Y, Ikeda U, Shimada K. Production of hepatocyte growth factor during acute myocardial infarction. Heart. 2000; 83: 450-455.
11. Rychli K, Richter B, Hohensinner PJ, et al. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart 2011; 97: 1158-1163.
12. Lamblin N, Susen S, Dagorn J, et al. Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am Heart J. 2005; 150: 137-143.
13. Malatino LS, Cataliotti A, Benedetto FA, et al. Hepatocyte growth factor and left ventricular geometry in end-stage renal disease. Hypertension. 2003; 41: 88-92.
14. Borawski J, Mysliwiec M. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients. Nephrol Dial Transplant. 2002; 17: 637-644.
15. Lee CT, Ng HY, Hsu CY, et al. Proinflammatory cytokines, hepatocyte growth factor and adipokines in peritoneal dialysis patients. Artif Organs. 2010; 34: E222-229.
16. Yu MA, Shin KS, Kim JH, et al. HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol. 2009; 20: 567-581.
17. Lai KN, Lam MF, Leung JC, et al. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Perit Dial Int. 2012; 32: 280-291.
18. Peters SA, Bakker M, den Ruijter HM, Bots ML. Added value of CAC in risk stratification for cardiovascular events: a systematic review. Eur J Clin Invest. 2012; 42: 110-116.
19. Sosnowski M, Kozakiewicz K, Syzdól M, et al. Coronary artery calcium in type 2 diabetes: a nested case-control study. Pol Arch Med Wewn. 2013; 123: 38-44.
20. Adamczyk T, Mizia-Stec K, Mizia M, et al. Biomarkers of calcification and atherosclerosis in patients with degenerative aortic stenosis in relation to concomitant coronary artery disease. Pol Arch Med Wewn. 2012; 122: 14-21.